Polymorphisms associated with ventricular tachyarrhythmias: Rationale, design, and endpoints of the 'diagnostic data influence on disease management and relation of genomics to ventricular tachyarrhythmias in implantable cardioverter/defibrillator patients (DISCOVERY)' study

Europace

Volumn 12, Issue 3, 2010, Pages 424-429

  Wieneke, Heinrich ^a   Spencker, Sebastian ^b   Svendsen, Jesper Hastrup ^c   Martinez, Juan Gabriel ^d   Strohmer, Bernhard ^e   Toivonen, Lauri ^f   Le Marec, Hervé ^g   Garcia, Javier ^h   Kaup, Bernd ⁱ   Soykan, Orhan ⁱ   Corrado, Domenico ^j   Siffert, Winfried ^k  

^a ELISABETH KRANKENHAUS ESSEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c University of Copenhagen   (Denmark)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e Medical University Hospital Salzburg   (Austria)

^f Meilahden Sairaala ^*  (Finland)

^g CHU de Nantes   (France)

^h HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

ⁱ MEDTRONIC INC   (United States)

^j UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^k UNIVERSITY HOSPITAL ESSEN   (Germany)

more..

Author keywords

G protein; Genome wide association study; Implantable cardioverter defibrillator; Single nucleotide polymorphisms; Ventricular arrhythmia

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN;

ARTICLE; CLINICAL TRIAL; DEFIBRILLATOR; DNA SEQUENCE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SUDDEN DEATH;

DEFIBRILLATORS, IMPLANTABLE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; LONGITUDINAL STUDIES; MULTICENTER STUDIES AS TOPIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TACHYCARDIA, VENTRICULAR;

EID: 77749320149     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eup444     Document Type: Article

References (35)

1. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008;51:288-96.
2. Huikuri HV, Mäkikallio TH, Raatikainen MJP, Perkiömäki J, Castellanos A, Myerburg RJ. Prediction of sudden cardiac death. Circulation 2003;108:110-5.
3. Farfel Z, Bourne HR, Iiri T. The expanding spectrum of G protein diseases. N Engl J Med 1999;340:1012-20.
4. + exchanger NHE1: effects on the sympathetic nervous system in heart failure. Cardiovasc Drug Rev 2007;25:123-31.
5. Lerman BB, Stein K, Engelstein ED, Battleman DS, Lippman N, Bei D et al. Mechanism of repetitive monomorphic ventricular tachycardia. Circulation 1995;92: 421-9.
6. Schreieck J, Dostal S, von Beckerath N, Wacker A, Flory M, Weyerbrock S et al. C825T polymorphism of the G-protein beta3 subunit gene and atrial fibrillation: association of the TT genotype with a reduced risk for atrial fibrillation. Am Heart J 2004;148:545-50.
7. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R et al. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998;18: 45-8.
8. Hengstenberg C, Schunkert H, Mayer B, Döring A, Löwel H, Hense HW et al. Association between a polymorphism in the G protein beta3 subunit gene (GNB3) with arterial hypertension but not with myocardial infarction. Cardiovasc Res 2001;49:820-7.
9. Gutersohn A, Naber C, Müller N, Erbel R, Siffert W. G protein beta3 subunit 825 TT genotype and post-pregnancy weight retention. Lancet 2000;355:1240-1.
10. Mitchell A, Pace M, Nurnberger J, Wenzel RR, Siffert W, Philipp T et al. Insulinmediated venodilation is impaired in young, healthy carriers of the 825T allele of the G-protein beta3 subunit gene (GNB3). Clin Pharmacol Ther 2005;77: 495-502.
11. Dobrev D, Wettwer E, Himmel HM, Kortner A, Kuhlisch E, Schuler S et al. G-protein beta(3)-subunit 825T allele is associated with enhanced human atrial inward rectifier potassium currents. Circulation 2000;102:692-7.
12. Wieneke H, Naber CN, Piaszek L, Sack S, Frey UH, Heusch G et al. Better identification of patients who benefit from implantable cardioverter defibrillators by genotyping the G protein beta3 subunit (GNB3) C825T polymorphism. Basic Res Cardiol 2006;101:447-51.
13. Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB et al. Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 1998;95:10140-5.
14. Wettschureck N, Rutten H, Zywietz A, Gehring D, Wilkie TM, Chen J et al. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med 2001;7:1236-40.
15. Frey UH, Lieb W, Erdmann J, Savidou D, Heusch G, Leineweber K et al. Characterization of the GNAQ promoter and association of increased Gq expression with cardiac hypertrophy in humans. Eur Heart J 2008;29:888-97.
16. Weinstein LS, Chen M, Xie T, Liu J. Genetic diseases associated with heterotrimeric G proteins. Trends Pharmacol Sci 2006;27:260-6.
17. Jia H, Hingorani AD, Sharma P, Hopper R, Dickerson C, Trutwein D. Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension 1999;34:8-14.
18. Frey UH, Adamzik M, Kottenberg-Assenmacher E, Jakob H, Manthey I, Broecker-Preuss M et al. A novel functional haplotype in the human GNAS gene alters Galphas expression, responsiveness to beta-adrenoceptor stimulation, and peri-operative cardiac performance. Eur Heart J 2009;30:1402- 10.
19. Frey UH, Hauner H, Jöckel KH, Manthey I, Brockmeyer N, Siffert W. A novel promoter polymorphism in the human gene GNAS affects binding of transcription factor upstream stimulatory factor 1, Galphas protein expression and body weight regulation. Pharmacogenet Genomics 2008;18:141-51.
20. Guttmacher AE, Collins FS. Genomic medicine - a primer. N Engl J Med 2002;347:512-20.
21. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007;5826:889-94.
22. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A et al. Genomewide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007;39:596-604.
23. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-9.
24. Newton-Cheh C, Eijgelsheim M, Rice KM, de Bakker PI, Yin X, Estrada K et al. Common variants at ten loci influence QT interval duration in the QTGEN study. Nat Genet 2009;41:399-406.
25. Pfeufer A, Sanna S, Arking DE, Müller M, Gateva V, Ehret GB et al. Common variants in ten loci modulate QT interval duration in individuals of European ancestry. Nat Genet 2009;41:407-14.
26. Kao WH, Arking DE, Post W, Rea TD, Sotoodehnia N, Prineas RJ et al. Genetic variations in nitric oxide synthase 1 adaptor protein are associated with sudden cardiac death in US white community-based populations. Circulation 2009;119: 940-51.
27. Saoudi N, Appl U, Anselme F, Voglimacci M, Cribier A. How smart should pacemakers be? Am J Cardiol 1999;83:180D-6D.
28. Sweeney MO, Wathen MS, Volosin K, Abdalla I, DeGroot PJ, Otterness MF et al. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation 2005;111:2898- 905.
29. Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM, EMPIRIC Trial Investigators. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol 2006;48:330-9.
30. Almendral J, Arribas F, Wolpert C, Ricci R, Adragao P, Cobo E et al. Dualchamber defibrillators reduce clinically significant adverse events compared with single-chamber devices: results from the DATAS (Dual chamber and Atrial Tachyarrhythmias Adverse events Study) trial. Europace 2008;10:528-35.
31. Frey UH, Bachmann HS, Peters J, Siffert W. PCR-amplification of GC-rich regions: 'slowdown PCR'. Nat Protoc 2008;3:1312-7.
32. Armitage P, Colton T. Tree-Structured Statistical Methods. Encyclopedia of Biostatistics. Vol. 6. John Wiley & Sons; 1999. p4561-73.
33. Johnson NL, Kotz S. Discrete Distributions. Boston: Houghton Mifflin Company; 1969. p58-60.
34. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW et al. Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004;110:3760-5.
35. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.